A Closer Look: With Only 60% Of China’s Sterile Drug Makers Passing New GMP Standard, What’s Next?
This article was originally published in PharmAsia News
Only 60% of sterile drug manufacturers passed the new GMP standard in China, as smaller companies chose to quit the market.
You may also be interested in...
China's State FDA Gets WHO Nod For Vaccine Regulatory System; Opens Global Market For Chinese Vaccine Makers
SHANGHAI - China's State FDA now complies with international standards for vaccine regulation and Chinese vaccine makers are eligible to apply for World Health Organization prequalification of vaccine products, WHO announced March 1, the same day that China implemented its newly revised good manufacturing practices (GMP) guidelines
SHANGHAI - China's State FDA released its long-awaited good manufacturing practices guidelines for pharmaceutical products Feb. 12, which will begin to be implemented in all new drug manufacturing sites in March
China's State Intellectual Property Office (SIPO) is drafting a new regulation on "service innovation" to encourage companies and researchers in the country to raise their investment in, and the conduct of, innovation. However, the move may also have an impact on the soaring drug discovery industry in China as it will mean higher payments to inventors with knock-on effects on local drug discovery and CROs.